TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31364889

Group type: EXPERIMENTAL
Intervention: E2/P4 (1 mg/100 mg, 0.5 mg/100 mg, 0.5 mg/50 mg, 0.25 mg/50 mg)
Number of subjects: 1835

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: E2/P4 and Placebo
Number of subjects: 1835
Study: 28741903

Group type: EXPERIMENTAL
Intervention: Self-collected nasal swabs
Number of subjects: 100
Study: 26295664

Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy
Number of subjects: 42
Study: 23389382

Group type: EXPERIMENTAL
Intervention: Duloxetine (10-week treatment)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (10-week treatment)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baseline comparison (DD vs HC)
Number of subjects: 41
Study: 22340221

Group type: EXPERIMENTAL
Intervention: BIS-guided group (Group A, BIS monitored and maintained between 40 - 60)
Number of subjects: 5228

Group type: COMPARATOR
Intervention: Control group (Group B, BIS monitored but screen covered)
Number of subjects: 5228

Group type: EXPERIMENTAL
Intervention: BIS-guided group
Number of subjects: 5228

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5228
Study: 19680131

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 3
Study: 17296917

Group type: EXPERIMENTAL
Intervention: Smoked cannabis (3.56% tetrahydrocannabinol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 50
Study: 15298423

Group type: EXPERIMENTAL
Intervention: Normothermia (Group I)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hypothermia (Group II)
Number of subjects: 23
Study: 12923404

Group type: EXPERIMENTAL
Intervention: 0.3 mg/day moxonidine
Number of subjects: 177

Group type: COMPARATOR
Intervention: 20 mg/day nitrendipine
Number of subjects: 177
Study: 9988808

Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg orally every 12 hours for 6 doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Terbutaline (5 mg orally every 4 hours for 72 hours)
Number of subjects: 20
Study: 8787984

Group type: EXPERIMENTAL
Intervention: Model-free sib-pair linkage analysis using 360 highly polymorphic marker loci
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sib-pair linkage analysis with deletion of parental marker genotypic information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sib-pair linkage analysis with misspecified marker allele frequency estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage testing procedure using a 10 or 20 cM map
Number of subjects: 0
Study: 2148827

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) (0.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixture of salbutamol and ipratropium bromide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Home nebulizer treatment (salbutamol, ipratropium bromide, mixture)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laboratory assessments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laboratory response
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hospital study
Number of subjects: 20
Study: 7437277

Group type: EXPERIMENTAL
Intervention: Dipyrone 1.0 g
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Paracetamol 1.0 g
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Dipyrone 1.0 g (tooth extraction)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Paracetamol 1.0 g (tooth extraction)
Number of subjects: 264
Study: 31902311

Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (600 mg·day-1 CurraNZ™)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (600 mg microcrystalline cellulose)
Number of subjects: 14
Study: 29788230

Group type: EXPERIMENTAL
Intervention: Trastuzumab/Pertuzumab-based chemotherapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Baseline TIL percentage
Number of subjects: 225
Study: 29692179

Group type: EXPERIMENTAL
Intervention: Intravenous belimumab plus standard therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab plus standard therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27154424

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU fortnightly for 6 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 24916911

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study: 21409548

Group type: EXPERIMENTAL
Intervention: Retropubic route (RPR)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Transobturator route (TOR)
Number of subjects: 88
Study: 21302741

Group type: EXPERIMENTAL
Intervention: Toothpaste containing hydroxyapatite
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium peroxide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo toothpaste (no active ingredient)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups (hydroxyapatite, calcium peroxide, placebo)
Number of subjects: 150
Study: 17573642

Group type: EXPERIMENTAL
Intervention: Pascal tonometer
Number of subjects: 205

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 205

Group type: COMPARATOR
Intervention: Pneumotonometry
Number of subjects: 205
Study: 16239629

Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Low-dose vitamin therapy
Number of subjects: 2155
Study: 12082358

Group type: EXPERIMENTAL
Intervention: GnRH agonist (gonadotropin-releasing hormone) administered via four monthly injections and estradiol patch during testing
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (10 women tested in the follicular phase of their menstrual cycles)
Number of subjects: 16
Study: 10399993

Group type: EXPERIMENTAL
Intervention: Streptokinase (1,500,000 IU over 30 to 60 min)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: TIMI grade 3 flow
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Myocardial score
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: End-systolic volume index
Number of subjects: 219
Study: 7872446

Group type: EXPERIMENTAL
Intervention: Topical 1% clotrimazole
Number of subjects: 54

Group type: COMPARATOR
Intervention: Topical 2% miconazole
Number of subjects: 54
Study: 29447733

Group type: EXPERIMENTAL
Intervention: Stroke risk model based on older age, Killip class 3 or 4, estimated glomerular filtration rate ≤45 ml/min/1.73 m2, hypertension history, and previous stroke.
Number of subjects: 22904

Group type: EXPERIMENTAL
Intervention: Stroke risk score sextiles (1.8%, 2.9%, 4.1%, 5.6%, 8.3%, and 10.9% event rates for increasing risk).
Number of subjects: 22904
Study: 28851323

Group type: EXPERIMENTAL
Intervention: 10 °C cold water immersion (CS)
Number of subjects: 17
Study: 25623485

Group type: EXPERIMENTAL
Intervention: Meropenem (standard arm)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (carbapenem-sparing arm)
Number of subjects: 454
Study: 23110916

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 126
Study: 21402752

Group type: EXPERIMENTAL
Intervention: Recalling immoral behavior
Number of subjects: 3

Group type: COMPARATOR
Intervention: Recalling moral behavior
Number of subjects: 3
Study: 18595128

Group type: EXPERIMENTAL
Intervention: 72 weeks of pegylated interferon and ribavirin treatment for genotype 1-infected slow responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: 48 weeks of pegylated interferon and ribavirin treatment for genotype 1-infected slow responders
Number of subjects: 0
Study: 16980814

Group type: EXPERIMENTAL
Intervention: BRCA1/2 genetic testing
Number of subjects: 157
Study: 12562461

Group type: EXPERIMENTAL
Intervention: Oral desensitization treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Strict elimination diet (Control)
Number of subjects: 59
Study: 10836202

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with 50 micrograms/day of 17 beta‐estradiol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9098205

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) at a dose of 0.16 mg/kg/min
Number of subjects: 140

Group type: COMPARATOR
Intervention: Dipyridamole (DIP) at a dose of 0.56 mg/kg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 140
Study: 8473679

Group type: EXPERIMENTAL
Intervention: BAY u 3405 (20 mg, single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PG D2 nasal insufflation
Number of subjects: 0
Study: 3701114

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study: 30074129

Group type: EXPERIMENTAL
Intervention: Kitazato warming kit (Group A - KK)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Sage warming kit (Group B - KS)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Kitazato warming kit (Group C - SK)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Sage warming kit (Group D - SS)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: KK (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: KS (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: SK (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: SS (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: SH (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HK (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HS (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HH (patients' own oocytes)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: eKK (egg-donation-derived embryos)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: eKS (egg-donation-derived embryos)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: eSK (egg-donation-derived embryos)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: eSS (egg-donation-derived embryos)
Number of subjects: 169
Study: 28541645

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d plus antipsychotics
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo plus antipsychotics
Number of subjects: 200
Study: 23557025

Group type: EXPERIMENTAL
Intervention: Doxycycline 20 mg b.i.d. for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Basic treatment only (Control)
Number of subjects: 64
Study: 23712985

Group type: EXPERIMENTAL
Intervention: Childhood appetitive traits (Desire to Drink, Enjoyment of Food, Satiety Responsiveness)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Having two obese parents
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Increasing Desire to Drink (DD) and decreasing Satiety Responsiveness (SR)
Number of subjects: 213
Study: 20946157

Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux (3 mg)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Idraparinux (2.5 mg)
Number of subjects: 757
Study: 18494634

Group type: EXPERIMENTAL
Intervention: Versajet Hydrosurgery System (n=22)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional surgical debridement (n=19)
Number of subjects: 41
Study: 16460668

Group type: EXPERIMENTAL
Intervention: Focused breathing induction (15 min recorded)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfocused attention induction (15 min recorded)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Worry induction (15 min recorded)
Number of subjects: 0
Study: 12539808

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Simvastatin (all doses)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 10766085

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation combined with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal surgery
Number of subjects: 0
Study: 8793166

Group type: EXPERIMENTAL
Intervention: Moexipril 3.75 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Moexipril 7.5 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 1613123

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 12
Study: 6699319

Group type: EXPERIMENTAL
Intervention: Jet nebulizer therapy with metaproterenol sulfate solution 15 mg in 2.3 ml
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Canister therapy with metered-dose metaproterenol sulfate (total 1.95 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Jet nebulizer therapy and Canister therapy
Number of subjects: 25
Study: 29386033

Group type: EXPERIMENTAL
Intervention: Unilateral Biportal Endoscopic (UBE) technique
Number of subjects: 141

Group type: COMPARATOR
Intervention: Open Lumbar Microdiscectomy (OLM)
Number of subjects: 141
Study: 26861468

Group type: EXPERIMENTAL
Intervention: Structured pharmacist review of medication (SPRM) with computerised clinical decision support software (CDSS)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Usual pharmaceutical care
Number of subjects: 737
Study: 25633683

Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 24371832

Group type: EXPERIMENTAL
Intervention: Water extracts of Graptopetalum paraguayense (WGP, 4 g/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20056852

Group type: EXPERIMENTAL
Intervention: High-carbohydrate drink (HI-HI) before PM exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonenergetic placebo (HI-LO) before PM exercise
Number of subjects: 10
Study: 18349701

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 50
Study: 16568465

Group type: EXPERIMENTAL
Intervention: Trauma dialogue
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Trauma narrative
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 169
Study: 15499981

Group type: EXPERIMENTAL
Intervention: 1% ephedrine nosedrop, antibiotic, antihistamine, and anisodamine (10 mg twice a day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 1% ephedrine nosedrop, antibiotic, and antihistamine
Number of subjects: 61
Study: 11371794

Group type: EXPERIMENTAL
Intervention: ORIF with bone graft supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: ORIF without bone graft
Number of subjects: 20
Study: 8995048

Group type: EXPERIMENTAL
Intervention: Free binocular virtual condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Free binocular real-world condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Static monocular real-world condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gender interaction with viewing conditions
Number of subjects: 30
Study: 7710217

Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg plus IM Ketorolac 30 mg (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural morphine 2 mg plus IM placebo (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural saline placebo plus IM Ketorolac 30 mg (Group C)
Number of subjects: 90
Study: 3358237

Group type: EXPERIMENTAL
Intervention: Field follow-up with reminder system
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Field follow-up
Number of subjects: 820

Group type: COMPARATOR
Intervention: Reminder system
Number of subjects: 820
Study: 30195447

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mesalazine 3 g once daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 27687369

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study: 25139873

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 640
Study: 23188412

Group type: EXPERIMENTAL
Intervention: recombinant LH (r-LH) administration during late follicular development stages
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: recombinant LH (r-LH) administration
Number of subjects: 20
Study: 20651460

Group type: COMPARATOR
Intervention: 15 mg Fe as ferric pyrophosphate
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 15 mg Fe as ferric pyrophosphate and 1.25 g DFAIII
Number of subjects: 168

Group type: COMPARATOR
Intervention: 15 mg Fe as ferrous sulfate
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 19213340

Group type: EXPERIMENTAL
Intervention: Basic treatment + small dose prednisone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Basic treatment + Chinese herbal medicine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Basic treatment only (Control Group A)
Number of subjects: 67
Study: 15798461

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented parenteral nutrition (GlnPN; glutamine target intake, 0.4 g kg day; n = 41)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (sPN; n = 39)
Number of subjects: 80
Study: 12662915

Group type: EXPERIMENTAL
Intervention: Ethyl oleate (EO) at 8 g/day in a single serving (approximately 0.1 g/kg)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Ethyl oleate (EO) at 16 g/day taken in two divided servings (approximately 0.2 g/kg)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Laboratory parameters (comprehensive laboratory data)
Number of subjects: 235
Study: 10227103

Group type: EXPERIMENTAL
Intervention: Clozapine (n = 35)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Typical neuroleptics (n = 29)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 64
Study: 9081353

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) of thoracic spine and pelvis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bone scintigraphy (BS) and/or unilateral bone marrow biopsy and aspiration (BMBA)
Number of subjects: 42
Study: 2071735

Group type: EXPERIMENTAL
Intervention: Participant modeling alone (n = 9)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Participant modeling with mother (n = 8)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard procedure control (n = 9)
Number of subjects: 26
Study: 6841411

Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contractions, 30 contractions a day for five weeks
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (supramaximal)
Number of subjects: 4
Study: 31784432

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplant (FMT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 45
Study: 30672238

Group type: EXPERIMENTAL
Intervention: Tongue acupuncture combined with rehabilitation training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment with acupuncture combined with rehabilitation training
Number of subjects: 80
Study: 27230965

Group type: EXPERIMENTAL
Intervention: APOL1 high-risk status (having two copies of the G1 or G2 risk alleles)
Number of subjects: 622

Group type: COMPARATOR
Intervention: APOL1 low-risk status (zero or one copy of the risk alleles)
Number of subjects: 622
Study: 26712382

Group type: EXPERIMENTAL
Intervention: Body weight‐based prednisolone dosing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Body surface area‐based prednisolone dosing
Number of subjects: 100
Study: 23434957

Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with 1 μg/kg of clonidine in normal saline (Group BC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with ketamine 0.5 mg/kg (Group BK)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine with fentanyl 1 mcg/kg (Group BF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Caudal analgesia with 0.75 ml/kg of 0.25% bupivacaine in normal saline (Group B)
Number of subjects: 80
Study: 20378497

Group type: EXPERIMENTAL
Intervention: L-LV (100 mg/m2)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: DL-LV (200 mg/m2)
Number of subjects: 876
Study: 19046201

Group type: EXPERIMENTAL
Intervention: Less-intensive SMBG
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: More-intensive SMBG
Number of subjects: 453

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 453
Study: 15843938

Group type: EXPERIMENTAL
Intervention: Three doses of oral antibiotics (neomycin and metronidazole) at the time of mechanical colon cleansing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: One dose of oral antibiotics
Number of subjects: 300

Group type: COMPARATOR
Intervention: No oral antibiotics
Number of subjects: 300
Study: 12377644

Group type: EXPERIMENTAL
Intervention: PVI 5-FU
Number of subjects: 254

Group type: COMPARATOR
Intervention: PVI 5-FU plus MMC
Number of subjects: 254
Study: 10605328

Group type: EXPERIMENTAL
Intervention: Nifidipine GITS 30 and 60 mg
Number of subjects: 51
Study: 9166464

Group type: EXPERIMENTAL
Intervention: Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) chemotherapy for 6 months
Number of subjects: 1229

Group type: COMPARATOR
Intervention: No adjuvant systemic therapy
Number of subjects: 1229